Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Q-linea AB (publ)
  6. Summary
    QLINEA   SE0011527845

Q-LINEA AB (PUBL)

(QLINEA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
06/15/2021 06/16/2021 06/17/2021 06/18/2021 06/21/2021 Date
137(c) 137.6(c) 137(c) 137(c) 135.6 Last
49 281 11 790 20 407 38 626 25 674 Volume
+0.29% +0.44% -0.44% 0.00% -1.02% Change
More quotes
Financials
Sales 2021 95,3 M 11,1 M 11,1 M
Net income 2021 -168 M -19,5 M -19,5 M
Net cash position 2021 56,7 M 6,59 M 6,59 M
P/E ratio 2021 -22,3x
Yield 2021 -
Sales 2022 375 M 43,7 M 43,7 M
Net income 2022 -60,9 M -7,09 M -7,09 M
Net cash position 2022 35,2 M 4,10 M 4,10 M
P/E ratio 2022 -61,4x
Yield 2022 -
Capitalization 4 002 M 463 M 466 M
EV / Sales 2021 41,4x
EV / Sales 2022 10,6x
Nbr of Employees 111
Free-Float 89,8%
More Financials
Company
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility... 
More about the company
Ratings of Q-linea AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about Q-LINEA AB (PUBL)
06/10Q LINEA  : has carried out a directed issue of 2.2 million shares, raising gross..
AQ
06/10Q LINEA  : announces intention to carry out a directed share issue
AQ
06/07Q LINEA  : initiates US 510(k) clinical study for ASTar
AQ
06/04Q LINEA  : Commercial evaluation of the ASTar system in Europe started
AQ
05/25Q LINEA  : Bulletin from annual general meeting in q-linea ab (publ)
AQ
05/04Q LINEA  : achieves CE-IVD approval for ASTar
AQ
04/29Q LINEA  : Invitation to presentation of Q-linea's Interim report Q1, 2021 on Ma..
AQ
04/26Q LINEA  : The proposal by the nomination committee of Q-linea AB (publ) for ele..
AQ
04/15Q LINEA  : publish the Annual report for 2020
AQ
03/31Q LINEA  : presents positive interim data from European trial
AQ
03/16Q LINEA  : signs first site for US study
AQ
03/10Q LINEA  : has received first order on ASTar
AQ
02/15Q LINEA  : Invitation to presentation of Q-linea's Year-end report 2020 on Febru..
AQ
2020Q LINEA  : initiates pivotal clinical study for ASTar
AQ
2020Q LINEA  : Jonas Jarvius, CEO of Q-linea presents at Life Science Day
AQ
More news
News in other languages on Q-LINEA AB (PUBL)

- No features available -

More news
Chart Q-LINEA AB (PUBL)
Duration : Period :
Q-linea AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends Q-LINEA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 185,00 SEK
Last Close Price 137,00 SEK
Spread / Highest target 35,0%
Spread / Average Target 35,0%
Spread / Lowest Target 35,0%
EPS Revisions
Managers and Directors
NameTitle
Jonas Sven Peter Jarvius President & Chief Executive Officer
Anders Lundin Chief Financial Officer & Head-Investor Relations
Erika Elisabeth Kjellberg-Eriksson Chairman
Tiziana di Martino Chief Medical Officer
Nils-Peter Kristensen Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
Q-LINEA AB (PUBL)-19.41%463
EXACT SCIENCES CORPORATION-4.51%21 705
GUARDANT HEALTH, INC.-6.73%12 155
BGI GENOMICS CO., LTD.-7.47%7 557
INVITAE CORPORATION-21.57%6 553
ADAPTIVE BIOTECHNOLOGIES CORPORATION-33.28%5 535